THE PERI-APPENDICEAL RED PATCH: A TRADEMARK SKIP LESION IN ULCERATIVE COLITIS
Corresponding author:
[email protected]
Received
27 September 2021
Revised
-
Accepted
02 November 2021
Available Online
15 November 2021
Abstract
CONVENTIONALLY, UC IS RECOGNIZED AS A DISEASE WITH CONTINUOUS MUCOSAL INFLAMMATION THAT EXTENDS FROM THE RECTUM TO THE PROXIMAL PART OF THE COLON, BUT DURING THE LAST DECADE, A PARTICULAR PATTERN OF COLITIS THAT INVOLVES THE DISTAL COLON WITH A NORMAL APP EARANCE MUCOSA INTERPOSED AND A WELL DEFINED AREA OF INFLAMMATION AROUND THE APPENDI X HAS BEEN HIGHLIGHTED. WE USED A TERTIARY CARE CENTER EVIDENCES TO ANALYZE THE CHARACTERISTICS OF UC PATIENTS WITH PARP. WE EVALUATED 76 PATIENTS WHO WENT TO OUR CLINIC FOR INVESTIGATING CHRONIC DIARRHEA SYNDROME BETWEEN JANUARY 2018 -DECEMBER 2020 AND F OR WHOM A DIAGNOSIS OF ULCERATIVE COLITIS WAS ESTABLISHED . ONLY 7 PATIENTS HAD ENDOSCOPICALLY ASPECT OF PARP (THIS HAPPENED DURING FOLLOW -UP ENDOSCOPY), ASPECT SUPPORTED A LSO BY THE HISTOLOGICAL DESCRIPTION (NANCY INDEX SCORE). DURING FOLLOW-UP, MOST PATIENTS WITH PARP KEPT THE SAME EXTENT OF LESIONS. CONCLUSIONS: WE CONFIRM THE PRESENCE OF PARP AS A “SKIP LESION” IN DISTAL UC, DIAGNOSTIC SUPPORTED ALSO BY THE HISTOPATHOLOG IST, AND EVEN THOUGH WE ARE CONFIDENT IN THE DIAGNOSIS OF ULCERATIVE COLITIS, ONE P ATIENT HAD A CROHN'S DISEASE PHENOTYPE SWITCH DURING THE EVOLUTION. NONETHELESS, WE CANNOT CONCLUDE THAT PARP HAS A ROLE IN THE EXTENSION OF LESIONS, REMISSION OR RELAPSE OF DISEASE, GIVEN THE FACT THAT WE DO NOT HAVE A SUFFICIENT GROUP OF ELIGIBLE PATIENT S, FOR WHICH REASON DETAILED STUDIES ARE NEEDED.
Keywords
CECAL PATCH
PERI -APPENDICEAL RED PATCH (PARP)
APPENDICEAL ORIFICE
Full Text
The body of this article is intentionally hidden on the public page. Please use the PDF reader or the PDF download for the complete text.
References
[1]
Faubion WA, Jr., Loftus EV, Sandborn WJ, Freese DK, Perrault J. Pediatric “PSC -IBD”: A descriptive report of associated inflam matory bowel disease among pediatric patients with psc. J Pediatr Gastroenterol Nutr 2001;33:296-300.
[2]
Odze R, Antonioli D, Peppercorn M, et al. Effect of topical 5 -aminosalicylic acid (5 –ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerativ e colitis. Am J Surg Pathol. 1993;17: 869 – 875.
[3]
Jorgensen KK, Grzyb K, Lundin KE, et a l. Inflammatory bowel disease in patients with primary sclerosing cholangitis: Clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis 2012;18:536-45
[4]
Sang Hyoung Park, Suk-Kyun Yang, et al. Atypical distribution of inflammation in newly diagnos ed ulcerative colitis is not rare. Can J Gastroenterol Hepatol. 2014 Mar; 28(3): 125–130.
[5]
S H Kroft, S J Stryker, M S Rao. Appendiceal involvement as a skip lesion in ulcerative colitis. Mod Pathol. . 1994 Dec;7(9):912-4.
[6]
Pera A, Bellando P, Caldera D, Ponti V, Astegiano M, Barletti C, David E, Arrigoni A, Rocca G, Verme G . Colonoscopy in inflammatory bowel disease. Diagnostic accuracy and propo sal of an endoscopic score. Gastroenterology. 1987;92(1):181.
[7]
Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D’Haens G, D’Hoore A, Mantzaris G, Novacek G, et al. Second European evidence -based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991–1030.
[8]
Paski, S. C., Wightman, R ., Robert, M.E., & Bernstein, C.N. The importance of reconginizing increased cecal inflammation in health and avoiding the misdiagnosis of nonspe cific colitis. The American Journal of Gastroenterology. 2007. 102(10), 2294-299
[9]
Morten Frisch, Bo V Pedersen, Rolland E Andersson. Appendicitis, mesenteric lymphadenitis, and subsequent risk of ulcerative colitis: cohort studies in Sweden and Denmark. BMJ . 2009; 338: b716
[10]
Carla Felice, Alessandro Armuzzi. Therapeutic Role of Appendectomy in Ulcerative Colitis: A Tangible Perspective? Journal of Crohn's and Colitis, Volume 13, Issue 2, February 2019, Pages 142 –